NEW YORK (GenomeWeb News) – Exiqon today reported that its first-half 2009 revenues rose 32 percent to DKK58.4 million ($11.2 million) compared to DKK44.5 million for the first half of 2008.

The Danish life science products and molecular diagnostics firm said that its second-quarter revenues rose 9 percent year over year to DKK30.6 million from DKK28 million.

Exiqon's net loss for the first half of the year was DKK81.2 million, or DKK2.86 per share.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.